De-escalation of axillary treatment in the event of a positive sentinel lymph node biopsy in cT1-2 N0 breast cancer treated with mastectomy: nationwide registry study (BOOG 2013-07)

被引：1

作者：

de Wild, Sabine R. ^{[1
,22
]}

van Roozendaal, Lori M. ^{[2
]}

de Wilt, Johannes H. W. ^{[3
]}

van Dalen, Thijs ^{[4
]}

van der Hage, Jos A. ^{[5
,6
]}

van Duijnhoven, Frederieke H.

Simons, Janine M. ^{[7
]}

Schipper, Robert-Jan ^{[8
]}

de Munck, Linda ^{[9
]}

van Kuijk, Sander M. J. ^{[10
]}

Boersma, Liesbeth J. ^{[11
]}

Linn, Sabine C. ^{[12
]}

Lobbes, Marc B., I ^{[13
]}

Poortmans, Philip M. P. ^{[14
,15
]}

Tjan-Heijnen, Vivianne C. G. ^{[16
]}

van de Vijver, Koen K. B. T. ^{[17
,18
]}

de Vries, Jolanda ^{[19
]}

Westenberg, A. Helen ^{[20
]}

Strobbe, Luc J. A. ^{[21
]}

Smidt, Marjolein L. ^{[1
]}

机构：

[1] Maastricht Univ, Med Ctr, Dept Surg, Grow Sch Oncol & Reprod, Maastricht, Netherlands

[2] Zuyderland Med Ctr, Dept Surg, Heerlen, Netherlands

[3] Radboud Univ Nijmegen, Med Ctr, Dept Surg, Nijmegen, Netherlands

[4] Erasmus MC, Dept Surg, Rotterdam, Netherlands

[5] Leiden Univ, Med Ctr, Dept Surg, Leiden, Netherlands

[6] Antoni Van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Surg, Amsterdam, Netherlands

[7] Erasmus MC, Dept Radiotherapy, Rotterdam, Netherlands

[8] Catharina Hosp, Dept Surg, Eindhoven, Netherlands

[9] Netherlands Comprehens Canc Org IKNL, Dept Res & Dev, Utrecht, Netherlands

[10] Maastricht Univ, Med Ctr, Dept Clin Epidemiol & Med Technol Assessment, Maastricht, Netherlands

[11] Maastricht Univ, Med Ctr, Dept Radiat Oncol Maastro, Grow Sch Oncol & Reprod, Maastricht, Netherlands

[12] Antoni Van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands

[13] Zuyderland Med Ctr, Dept Med Imaging, Sittard Geleen, Netherlands

[14] Iridium Netwerk, Dept Radiat Oncol, Antwerp, Belgium

[15] Univ Antwerp, Fac Med & Hlth Sci, Antwerp, Belgium

[16] Maastricht Univ, Med Ctr, Dept Med Oncol, Maastricht, Netherlands

[17] Netherlands Canc Inst Antoni Van Leeuwenhoek, Dept Pathol, Amsterdam, Netherlands

[18] Univ Hosp Ghent, Canc Res Inst Ghent, Dept Pathol, Ghent, Belgium

[19] Tilburg Univ, Dept Psychol & Hlth, Tilburg, Netherlands

[20] Radiotherapiegroep Arnhem, Dept Radiat Oncol, Arnhem, Netherlands

[21] Canisius Wilhelmina Hosp, Dept Surg, Nijmegen, Netherlands

[22] Maastricht Univ, Med Ctr, Dept Surg, POB 5800, NL-6202 AZ Maastricht, Netherlands

来源：

BRITISH JOURNAL OF SURGERY | 2024年 / 111卷 / 04期

关键词：

FOLLOW-UP; CLINICAL-TRIALS; OLDER PATIENTS; PHASE-III; DISSECTION; RECURRENCE; RADIATION; SURVIVAL; OMISSION; ONCOLOGY;

D O I：

10.1093/bjs/znae077

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

Background Trials have demonstrated the safety of omitting completion axillary lymph node dissection in patients with cT1-2 N0 breast cancer operated with breast-conserving surgery who have limited metastatic burden in the sentinel lymph node. The aim of this registry study was to provide insight into the oncological safety of omitting completion axillary treatment in patients operated with mastectomy who have limited-volume sentinel lymph node metastasis.Methods Women diagnosed in 2013-2014 with unilateral cT1-2 N0 breast cancer treated with mastectomy, with one to three sentinel lymph node metastases (pN1mi-pN1a), were identified from the Netherlands Cancer Registry, and classified by axillary treatment: no completion axillary treatment, completion axillary lymph node dissection, regional radiotherapy, or completion axillary lymph node dissection followed by regional radiotherapy. The primary endpoint was 5-year regional recurrence rate. Secondary endpoints included recurrence-free interval and overall survival, among others.Results In total, 1090 patients were included (no completion axillary treatment, 219 (20.1%); completion axillary lymph node dissection, 437 (40.1%); regional radiotherapy, 327 (30.0%); completion axillary lymph node dissection and regional radiotherapy, 107 (9.8%)). Patients in the group without completion axillary treatment had more favourable tumour characteristics and were older. The overall 5-year regional recurrence rate was 1.3%, and did not differ significantly between the groups. The recurrence-free interval was also comparable among groups. The group of patients who did not undergo completion axillary treatment had statistically significantly worse 5-year overall survival, owing to a higher percentage of non-cancer deaths.Conclusion In this registry study of patients with cT1-2 N0 breast cancer treated with mastectomy, with low-volume sentinel lymph node metastasis, the 5-year regional recurrence rate was low and comparable between patients with and without completion axillary treatment. The aim of this registry study was to provide insight into the oncological safety of omitting completion axillary treatment in patients with cT1-2 N0 breast cancer treated with mastectomy, who have limited sentinel lymph node involvement. The 5-year regional recurrence rate was low (overall 1.3%) and comparable between treatment groups. Omitting completion axillary treatment appears to be safe in selected patients.

引用

页数：10

共 48 条

[1]

American Joint Committee on Cancer, Cancer Staging System

[2] Patient-reported outcomes one year after positive sentinel lymph node biopsy with or without axillary lymph node dissection in the randomized SENOMAC trial [J].

Appelgren, Matilda ;

Sackey, Helena ;

Wengstrom, Yvonne ;

Johansson, Karin ;

Ahlgren, Johan ;

Andersson, Yvette ;

Bergkvist, Leif ;

Frisell, Jan ;

Lundstedt, Dan ;

Ryden, Lisa ;

Sund, Malin ;

Alkner, Sara ;

Offersen, Birgitte Vrou ;

Tvedskov, Tove Filtenborg ;

Christiansen, Peer ;

de Boniface, Jana .

BREAST, 2022, 63 :16-23

[3] Morbidity Results From the NSABP B-32 Trial Comparing Sentinel Lymph Node Dissection Versus Axillary Dissection [J].

Ashikaga, Takamaru ;

Krag, David N. ;

Land, Stephanie R. ;

Julian, Thomas B. ;

Anderson, Stewart J. ;

Brown, Ann M. ;

Skelly, Joan M. ;

Harlow, Seth P. ;

Weaver, Donald L. ;

Mamounas, Eleftherios P. ;

Costantino, Joseph P. ;

Wolmark, Norman .

JOURNAL OF SURGICAL ONCOLOGY, 2010, 102 (02) :111-118

[4] Radiotherapy or Surgery of the Axilla After a Positive Sentinel Node in Breast Cancer: 10-Year Results of the Randomized Controlled EORTC 10981-22023 AMAROS Trial [J].

Bartels, Sanne A. L. ;

Donker, Mila ;

Poncet, Coralie ;

Sauve, Nicolas ;

Straver, Marieke E. ;

van de Velde, Cornelis J. H. ;

Mansel, Robert E. ;

Blanken, Charlotte ;

Orzalesi, Lorenzo ;

Klinkenbijl, Jean H. G. ;

van der Mijle, Huub C. J. ;

Nieuwenhuijzen, Grard A. P. ;

Veltkamp, Sanne C. ;

van Dalen, Thijs ;

Marinelli, Andreas ;

Rijna, Herman ;

Snoj, Marko ;

Bundred, Nigel J. ;

Merkus, Jos W. S. ;

Belkacemi, Yazid ;

Petignat, Patrick ;

Schinagl, Dominic A. X. ;

Coens, Corneel ;

van Tienhoven, Geertjan ;

van Duijnhoven, Frederieke ;

Rutgers, Emiel J. T. .

JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (12) :2159-+

[5] The Association Between Surgical Axillary Staging, Adjuvant Treatment Use and Survival in Older Women with Early Stage Breast Cancer: A Population-Based Study [J].

Castelo, Matthew ;

Sutradhar, Rinku ;

Faught, Neil ;

Mata, Danilo Giffoni M. M. ;

Hahn, Ezra ;

Nguyen, Lena ;

Paszat, Lawrence ;

Rodin, Danielle ;

Trebinjac, Sabina ;

Fong, Cindy ;

Rakovitch, Eileen .

ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (7) :3901-3912

[6] Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V [J].

Colleoni, Marco ;

Sun, Zhuoxin ;

Price, Karen N. ;

Karlsson, Per ;

Forbes, John F. ;

Thurlimann, Beat ;

Gianni, Lorenzo ;

Castiglione, Monica ;

Gelber, Richard D. ;

Coates, Alan S. ;

Goldhirsch, Aron .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (09) :927-+

[7] The generalisability of randomised clinical trials: an interim external validity analysis of the ongoing SENOMAC trial in sentinel lymph node-positive breast cancer [J].

de Boniface, Jana ;

Ahlgren, Johan ;

Andersson, Yvette ;

Bergkvist, Leif ;

Frisell, Jan ;

Lundstedt, Dan ;

Olofsson Bagge, Roger ;

Ryden, Lisa ;

Sund, Malin ;

Christiansen, Peer ;

Filtenborg Tvedskov, Tove ;

Offersen, Birgitte Vrou ;

Reimer, Toralf ;

Kuehn, Thorsten ;

Kontos, Michalis ;

Gentilini, Oreste ;

Reitsamer, Roland .

BREAST CANCER RESEARCH AND TREATMENT, 2020, 180 (01) :167-176

[8] Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: the randomized controlled SENOMAC trial [J].

de Boniface, Jana ;

Frisell, Jan ;

Andersson, Yvette ;

Bergkvist, Leif ;

Ahlgren, Johan ;

Ryden, Lisa ;

Bagge, Roger Olofsson ;

Sund, Malin ;

Johansson, Hemming ;

Lundstedt, Dan .

BMC CANCER, 2017, 17

[9] Older cancer patients in cancer clinical trials are underrepresented. Systematic literature review of almost 5000 meta- and pooled analyses of phase III randomized trials of survival from breast, prostate and lung cancer [J].

Dunn, Cita ;

Wilson, Andrew ;

Sitas, Freddy .

CANCER EPIDEMIOLOGY, 2017, 51 :113-117

[10] Outcomes of Sentinel Lymph Node-Positive Breast Cancer Patients Treated with Mastectomy Without Axillary Therapy [J].

FitzSullivan, Elizabeth ;

Bassett, Roland L. ;

Kuerer, Henry M. ;

Mittendorf, Elizabeth A. ;

Yi, Min ;

Hunt, Kelly K. ;

Babiera, Gildy V. ;

Caudle, Abigail S. ;

Black, Dalliah M. ;

Bedrosian, Isabelle ;

Reyna, Chantal ;

Teshome, Mediget ;

Meric-Bernstam, Funda ;

Hwang, Rosa .

ANNALS OF SURGICAL ONCOLOGY, 2017, 24 (03) :652-659

← 1 2 3 4 5 →